Herz Und Diabeteszentrum NRW Bad Oeynhausen Universitaetsklinik Der Ruhr-Universitaet Bochum
Verified site
Bad Oeynhausen, Germany
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
The study involves adults with Type 2 Diabetes whose blood sugar levels are not well controlled despite taking metformin, with or without a Sodium-glucose cotransporter-2 inhibitor. Participants will receive either a monthly injection of Maridebart Cafraglutide or a weekly injection of Semaglutide in addition to their current medicines.
The aim is to see whether the monthly treatment works at least as well as the weekly treatment in lowering blood sugar, measured by changes in HbA1c and also looking at changes in body weight. After enrollment, participants will be assigned to one of the two injection schedules and will be followed for several months with regular clinic visits where blood samples and weight are taken to track progress.
The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.
5 criteria
18 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Bad Oeynhausen, Germany
Leipzig, Germany
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
This investigational drug is given as a solution for injection under the skin once a month. It is still in clinical trials and not yet approved for general medical use, so information about it is limited to research reports. It is being studied for people with type 2 diabetes whose blood sugar is not well controlled with metformin, with or without an SGLT‑2 inhibitor. The medicine works by copying a natural hormone called GLP‑1, which helps the pancreas release insulin and lowers the amount of sugar produced by the liver; it belongs to the class of GLP‑1 receptor agonist peptides.
This approved medication is injected under the skin once a week as a liquid solution. It is widely used and well documented in medical literature for the treatment of type 2 diabetes and for weight management. It helps lower blood sugar by acting like the body’s own GLP‑1 hormone, stimulating insulin release after meals and reducing glucose production by the liver. Semaglutide is classified as a GLP‑1 receptor agonist, a type of peptide drug.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.